Coherus Oncology's major customers
McKesson accounted for 43% of Coherus Oncology's revenue in FY 2025, about the same as 43% a year earlier.
Get an email when Coherus Oncology's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Coherus Oncology
Customers that Coherus Oncology named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| McKessonMCK | 43% | from 43% | 7 years | FY 2025 · filed 9 Mar 2026 |
| CencoraCOR | 36% | ▼ from 43% | 2 years | FY 2025 · filed 9 Mar 2026 |
| Cardinal | 20% | ▲ from 13% | 7 years | FY 2025 · filed 9 Mar 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Daiichi Sankyo | 100% | last FY 2017 | 1 year | FY 2017 · filed 28 Feb 2019 |
| Baxalta | 99% | last FY 2016 | 3 years | FY 2016 · filed 28 Feb 2019 |
| AmerisourceBergen | 38% | last FY 2024 | 6 years | FY 2024 · filed 17 Mar 2025 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API